Estrogen Receptor β as a Pharmaceutical Target

Trends Pharmacol Sci. 2017 Jan;38(1):92-99. doi: 10.1016/ Epub 2016 Dec 13.


A major issue in clinical endocrinology today is how to use hormones to achieve the health benefits that they clearly can provide but avoid the negative side effects, that is, how to develop more precise medicines. This problem of how to use hormones is pervasive in clinical endocrinology. It is true for estrogen, progesterone, androgen, vitamin D, and thyroid hormone, and the problem is amplified in the case of new ligands for the more recently discovered nuclear receptors. Selective targeting of hormone receptor subtypes is one attractive way to harness the beneficial effects of hormones while reducing unwanted side effects. Here, we focus on estrogen receptor (ER)β, which has promise as a selective target in hormone replacement therapy, and in breast and prostate cancers.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Breast Neoplasms / chemistry
  • Breast Neoplasms / drug therapy
  • Estrogen Receptor beta / agonists
  • Estrogen Receptor beta / drug effects*
  • Estrogen Receptor beta / physiology
  • Estrogen Replacement Therapy
  • Female
  • Humans
  • Ligands
  • Male
  • Oxysterols / pharmacology
  • Precision Medicine
  • Prostatic Neoplasms / chemistry
  • Prostatic Neoplasms / drug therapy


  • Estrogen Receptor beta
  • Ligands
  • Oxysterols